Executive summary: US patent 11,896,717 is a method-agnostic-to-dosing-parameter suite for once-daily oral sustained-release ruxolitinib phosphate built around plasma exposure “windows” (notably Cmax/C12h ≤ 10 and t1/2 3.5 to 11 hours) and dose levels 10 to 60 mg (free-base basis). The claim set is structured to capture (i) ER tablet/capsule presentations and (ii) therapeutic use in myelofibrosis, polycythemia vera, and graft-versus-host disease, with dependent method claims specifying common subtypes and a clinical biomarker direction (improved thrombocytopenia/anemia vs immediate-release). The landscape for design-around is largely a function of whether a competitor can move plasma ratios and/or half-life outside the claimed windows while maintaining acceptable efficacy and safety, or route around with non-ER dosing or non-phosphate forms not meeting the “ruxolitinib phosphate” limitation.
US Patent 11,896,717 scope and claims: what is protected for once-daily oral sustained-release ruxolitinib phosphate
Core protected subject matter: A single-entity oral sustained-release dosage form with defined exposure metrics and dose range, plus therapeutic methods using that dosage form.
Independent claim 1: the claim “hinges”
Claim 1 contains five lock points:
-
Drug identity
- Ruxolitinib phosphate (not “ruxolitinib” generically).
-
Dosage form type
- Oral sustained release dosage form, with “a means for sustained release.”
-
Dose range
- 10 to 60 mg ruxolitinib phosphate on a free base basis.
-
Exposure profile
- Cmax/C12h of 10 or less.
- Mean t1/2 3.5 to 11 hours.
-
Oral suitability and human exposure
- Administration results in the exposure windows “to a human” (for t1/2).
- The Cmax and C12h ratio is also conditioned on “administration … results in” that ratio.
Interpretation for infringement mapping
- “Means for sustained release” is broad. It can cover matrix, diffusion, osmotic systems, or multilayer approaches, so long as sustained release is achieved.
- The exposure metrics make the claim product-by-performance. A formulation that is nominally ER but yields Cmax/C12h > 10 or t1/2 outside 3.5–11 hours can fall outside claim 1 even if it contains the same active and is ER.
- “Free base basis” is a significant conversion anchor for competitors. If a competitor’s label uses salt amount that does not correspond to 10–60 mg free-base equivalent, it can avoid the numerical range even if the salt concentration is similar.
What exactly do the plasma exposure limits mean (Cmax/C12h and t1/2) for US 11,896,717?
Claim 1 uses two quantitative PK constraints that define the effective boundary for a sustained-release design.
Cmax to C12h ratio constraint (≤ 10)
- The claim requires mean ratio, not necessarily individual ratio, and does not specify a sampling scheme beyond Cmax and 12-hour concentration.
- Practical consequence: a formulation that produces a relatively flat exposure through 12 hours (lower peak relative to later concentration) is more likely to sit within the claim.
Half-life window (3.5 to 11 hours)
- This window is wide enough to cover many ER profiles for small molecules, but still creates a bright-line exit if the formulation yields a substantially shorter or longer effective half-life.
- The claim uses mean t1/2, so population averaging matters.
How dependent claim 11–13 tightens the ratio
- Claim 11: 1 to 10
- Claim 12: 2 to 7
- Claim 13: t1/2 4 to 8 hours
Scope effect: Dependent claims narrow the independent claim’s exposure window. In practice, infringement analysis often focuses first on claim 1; but these dependents can matter for litigation strategy because they offer narrower “landing zones” for proving infringement with PK studies that show a tighter ratio range.
How broad are the dosage and presentation elements (10–60 mg, tablet vs capsule)
Dosage amount coverage (claims 2–10)
Claim 1 covers 10 to 60 mg. Dependent claims list specific points:
- 10, 12.5, 20, 25, 30, 37.5, 40, 50, 60 mg (free-base basis)
Scope effect: Listing specific amounts typically signals that the specification includes examples at those strengths and that the patent holder views those as commercially relevant embodiments. Competitors targeting intermediate or non-listed strengths still remain within claim 1 if they are within the 10–60 mg range.
Dosage form type (claims 15–16)
- Claim 15: tablet
- Claim 16: capsule
Scope effect: These dependents do not restrict claim 1; they show two covered embodiments. If a competitor uses another oral ER format (e.g., multiparticulate sachet, mini-tablet-filled capsule without being “a capsule” under claim construction), infringement depends on how “tablet” and “capsule” are construed. If those terms are interpreted broadly, the odds of non-infringement via format are reduced.
What treatment indications are covered and how dependent method claims narrow disease scope (claims 18–23)
Independent method claim 18
A method for treating a disease selected from:
- Myelofibrosis
- Polycythemia vera
- Graft versus host disease (GVHD)
by administering the claimed once-daily oral sustained-release dosage form.
Disease subtype dependents
- Claim 19: myelofibrosis
- Claim 20: PMF, PV-MF, post-ET-MF
- Claim 21: polycythemia vera
- Claim 22: graft versus host disease
Outcome direction dependent (claim 23)
- “Reduction in thrombocytopenia or anemia relative to an immediate-release dosing regimen.”
Scope effect: Claim 23 is not strictly a different active ingredient or formulation. It adds a performance/clinical endpoint relationship to a comparator (immediate-release regimen). A competitor’s study design and comparator choice can influence whether this dependent claim is met, but it does not need to be met to potentially infringe claim 18.
What formulations are “captured” by claim language beyond ER matrices (design-around boundaries)
Even without the written description, claim 1’s structure captures most common ER architectures as long as PK endpoints land within the defined windows.
ER technologies likely within “means for sustained release”
- Hydrophilic or hydrophobic matrix tablets
- Diffusion-controlled matrices
- Osmotic release systems
- Multiparticulates embedded in ER tablets/capsules
Where design-around is most plausible
-
PK window escape
- Drive Cmax/C12h above 10 and/or move mean t1/2 below 3.5 or above 11.
- This is the most direct method-level design workaround because the active and salt remain the same.
-
Dose range escape
- Use strength outside 10–60 mg free-base range.
- If commercial development requires those strengths, this is harder.
-
Salt form escape
- Replace ruxolitinib phosphate with another salt or form not meeting the literal “ruxolitinib phosphate” limitation.
- This can be difficult due to bioequivalence and regulatory expectations, but it is a clear claim boundary.
-
Non-ER or non-once-daily dosing
- Claim 18 explicitly requires once per day administration.
- Even if a formulation is sustained release, dosing frequency outside “once per day” can avoid claim 18 while still potentially implicating claim 1 depending on what infringement theory is pursued for the formulation itself.
How to use this patent in freedom-to-operate: claim chart logic for infringement vs invalidity
Claim chart “hit list” for infringement
A formation that meets all of the following likely maps cleanly to claim 1:
- Oral ER dosage form containing ruxolitinib phosphate
- Strength corresponding to 10–60 mg free-base
- PK from human study showing:
- mean Cmax/C12h ≤ 10
- mean t1/2 between 3.5 and 11 hours
If therapeutic dosing is also once daily, method claim 18 is implicated when prescribing for MF/PV/GVHD.
Where invalidity arguments typically attack
- Lack of novelty or obviousness often target whether other ER ruxolitinib phosphate formulations already disclose the same PK metrics and dose strengths.
- Enablement/clarity issues typically focus on how the patent supports obtaining the PK windows across the whole claimed dose range and with robust sustained release means.
Because claim 1 is performance-defined, the novelty/obviousness analysis is typically PK-data dependent. That makes prior art clinical PK study designs and sampling time points especially important.
How strong is the patent estate for this concept (what matters for enforcement leverage)
Within the four corners of the claims you provided, strength is driven by:
- The patent covers both composition-of-dosage-form (claim 1 and dependents) and methods (claim 18 and dependents).
- The exposure thresholds create litigation leverage because a challenger must test PK and often rely on data.
But enforcement depends heavily on:
- The ability to match competitor products to the exact salt and PK windows.
- Availability of competitor data or ability to obtain it via discovery or label/PIB constraints.
Orange Book and generic entry risk for ER ruxolitinib phosphate: what risk vectors exist
Key risk vector: If a generic or follow-on biologically/chemically small molecule strategy targets an ER ruxolitinib phosphate product with similar PK windows, it would likely face patent infringement risk under claim 1 and method claims under claim 18.
Two main pathways to reduced risk:
- Different PK outcome (escape Cmax/C12h and/or t1/2)
- Different salt form or dosing profile (avoid literal “ruxolitinib phosphate” or “once per day” for method claims)
What to watch in filings and labels:
- Strengths at/within the 10–60 mg free-base equivalents.
- “Sustained release” claims in labeling.
- Pharmacokinetic summaries including Cmax and values at 12 hours, allowing Cmax/C12h computation.
How this ER PK framework compares with typical ruxolitinib ER patents (what’s different)
Most ruxolitinib IP estates for ER dosage forms rely on:
- ER composition limitations (matrices, polymers, coatings)
- Specific release-rate parameters
US 11,896,717 instead places primary emphasis on human plasma exposure ratio and half-life. This can be more robust against “different formulation” design-around attempts if the formulation-by-performance still lands inside the PK window.
From a challenger’s standpoint, this increases the technical burden: they must generate or locate PK evidence to establish that the competitor’s product yields ratios outside ≤10 or half-life outside 3.5–11 hours.
Patent strategy implications for licensing or litigation
Licensing posture
A license proposal for an ER ruxolitinib phosphate competitor typically hinges on:
- Whether the candidate product is designed to land within the same PK endpoints.
- Whether the candidate can sustain those endpoints across multiple strengths (claim 1’s dose range suggests multi-strength relevance).
Litigation posture
- Plaintiff tends to focus on claim 1 with PK comparability evidence.
- Method claims (18–23) can be used to support broader damages and to pressure settlement where prescribing for MF/PV/GVHD is central to commercial value.
Key Takeaways
- US 11,896,717 is centered on a once-daily oral sustained-release ruxolitinib phosphate product defined by dose (10–60 mg free-base) and human PK windows (Cmax/C12h ≤ 10; t1/2 3.5–11 hours).
- Dependent claims lock in practical commercialization points: specific strengths, tablet/capsule formats, tighter PK windows, and indications across myelofibrosis (PMF, PV-MF, post-ET-MF), polycythemia vera, and GVHD.
- Design-around most plausibly comes from escaping the PK boundaries, changing salt identity, or changing dosing frequency to avoid method claim 18.
- For generic or follow-on ER products, the main technical litigation risk is matching the claimed PK endpoints while also using the exact salt form.
FAQs
-
Does US 11,896,717 cover any sustained-release ruxolitinib phosphate, or only those meeting Cmax/C12h and half-life windows?
It is limited to ER products whose human administration yields the claimed Cmax/C12h and t1/2 metrics.
-
If a competitor’s ER ruxolitinib phosphate product is within the 10–60 mg range but has Cmax/C12h above 10, does it still infringe claim 1?
It would not satisfy the claim 1 exposure constraint, which is required in the claim language.
-
Are PMF, PV-MF, and post-ET-MF all explicitly covered?
Yes. They are recited in dependent claim 20 as myelofibrosis subtypes within the method claim family.
-
Can a competitor avoid method claim 18 by dosing more than once per day even if the formulation is sustained-release?
Claim 18 requires administration once per day, so dosing frequency is a key boundary for that method claim.
-
Which claim elements are most “literal” versus most likely to be proven by data in litigation?
“Ruxolitinib phosphate,” oral sustained release, and strength are literal. Cmax/C12h and t1/2 are inherently data-driven, making PK evidence central.
References (APA)
- US Patent 11,896,717. (n.d.). Claims as provided in prompt.